Singapore, February 15, 2019 – Immunotherapy drugs such as PD-L1 checkpoint inhibitors represent the front-line treatment for kidney cancer. But immunotherapy is expensive, benefits only a subset of patients and is futile in the majority of patients. Now, researchers from National Cancer Centre Singapore and Lucence Diagnostics have conducted a study using Lucence’s molecular test, CLEARScore™, to predict immunotherapy response for kidney cancer. The findings from this study will be presented at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) held in San Francisco this week.

CLEARScore™ is a molecular test that predicts treatment response for kidney cancer. It is an algorithm involving eight genes in the tumor, which classifies kidney cancer by molecular type. This test has been used to successfully predict treatment response of kidney cancer patients to tyrosine kinase inhibitors, a type of targeted therapy. The results were published in 2015 in European Urology, the world’s top urology journal.

In this new study, CLEARScore™ was investigated in correlation with anti-PD-L1 inhibitors and immune cell markers in 36 kidney cancer patients. The results showed that the gene expression score of the eight genes correlated with immune cell infiltration and clinical response to anti-PD-L1 inhibitors in a subset of patients. This indicates that multigene score should be investigated as a biomarker to select patients who are likely to respond to immunotherapy. The study was conducted by National Cancer Centre Singapore and Lucence Diagnostics, in collaboration with the Diagnostics Development (DxD) Hub led by A*ccelerate (A*STAR), Singapore General Hospital and OncoCare Cancer Centre.

“Immunotherapy is a major breakthrough in our battle against kidney cancer. It is however expensive and may have side effects. Having a test that can distinguish whether a kidney cancer patient will or will not benefit from anti-PD-L1 immunotherapy would be of high clinical value. Such tests have not been previously reported, and CLEARScore™ is a promising and exciting advance towards more precise selection of cancer patients for treatment,’’ said Dr Ravindran Kanesvaran, Senior Consultant, Department of Medical Oncology, National Cancer Centre Singapore, who designed and led the study.

“This is the first study to report the correlation of a multigene score with immune phenotypes in kidney cancer. We are excited about the potential of using our CLEARScore™ test to help kidney cancer patients avoid futile treatments and prolong their lives. To further establish the clinical utility of this test for immunotherapy, we will be conducting a multinational study on a larger cohort of kidney cancer patients,’’ said Dr Yukti Choudhury, Chief Technology Officer, Lucence Diagnostics, who will be presenting the study at ASCO GU.

Kidney cancer is among the ten most common cancers in men and women across the world. In 2018, there were over 400,000 new cases of kidney cancer globally[1].

 

About National Cancer Centre Singapore

National Cancer Centre Singapore (NCCS) provides a holistic and multi-disciplinary approach to cancer treatment and patient care. We see close to 65 per cent of the public sector oncology cases, and they are benefiting from the sub-specialisation of our clinical oncologists.  NCCS is also accredited by the US-based Joint Commission International for its quality patient care and safety. To deliver among the best in cancer treatment and care, our clinicians work closely with our scientists who conduct robust cutting-edge clinical and translational research programmes which are internationally recognised. NCCS will also launch its Proton Beam Therapy programme at its new centre. NCCS strives to be a global leading cancer centre, and shares its expertise and knowledge by offering training to local and overseas medical professionals.
www.nccs.com.sg

About Lucence Diagnostics

Lucence Diagnostics is a genomic medicine company founded to fulfil its vision of a world without avoidable cancer deaths. The company invents non-invasive blood tests that improve cancer detection and treatment selection. Lucence targets the most common cancers in Asia using its proprietary technology and AI platform. Lucence is headquartered in Singapore with offices in San Francisco and Hong Kong. Its services are delivered worldwide through an accredited central laboratory.
www.lucencedx.com

About Diagnostics Development (DxD) Hub

DxD Hub is Singapore’s national initiative led by public innovation and enterprise office, A*ccelerate Technologies (formerly ETPL). DxD Hub’s mission is to fast-track the transformation of early-stage research into clinically validated diagnostic devices that are ready for market adoption.

About Singapore General Hospital

Singapore General Hospital, a member of Singapore Health Services, is the public sector’s flagship hospital. Established in 1821, SGH is Singapore’s largest acute tertiary hospital with 1,700 beds and national referral centre offering a comprehensive range of 39 clinical specialties on its campus. Every year, about 1 million Singaporeans benefit from medical care delivered by its 800 specialists. As an academic healthcare institution and the bedrock of medical education, SGH plays a key role in nurturing doctors, nurses and allied health professionals, and is committed to innovative translational and clinical research to provide the best care and outcomes to patients. www.sgh.com.sg

 

For media queries and clarifications, please contact:

National Cancer Centre Singapore
Ms Gillian Tan
Senior Executive, Corporate Communications
Office: 6236 9529
HP: 8157 3671
Email: [email protected]

Lucence Diagnostics
Ms Elena Tan
Director, Communications
Office: 6906 8567
Email: [email protected]

 Diagnostics Development Hub
Ms Ho Yuan Lu
Business Development
HP: 9682 5311
Email: [email protected]

 

[1] GLOBOCAN 2018

Singapore, January 30, 2019 – Lucence Diagnostics today announced the opening of its new headquarters and molecular diagnostics laboratory in Singapore. The opening was officiated by Dr Koh Poh Koon, Senior Minister of State, Ministry of Trade and Industry.

Lucence invents blood tests for rapid and non-invasive cancer detection. The company is a spin-off from the Agency for Science, Technology and Research (A*STAR). It was set up in 2016 by founder and CEO Dr Tan Min-Han. Lucence’s mission is to reduce avoidable cancer deaths through early detection and better treatment selection. It focuses on the most common cancers in Asia, such as cancers of the breast, colon, liver, lung and nose.

Such cancer blood tests are referred to as a liquid biopsy. Conventional tissue biopsy requires the surgical removal of tissue from the body, which is invasive and slow. Lucence’s liquid biopsy tests are non-invasive, fast and affordable because it only requires one draw of blood.

Since its founding, Lucence has raised S$12.9 million in seed funding to deliver its liquid biopsy tests to patients in public and private healthcare institutions in Asia. Lucence has expanded its business operations to Hong Kong and San Francisco. Its blood tests are currently available in 8 countries in the region – India, Hong Kong, Philippines, Malaysia, Myanmar, Thailand, Vietnam and Singapore. Lucence’s new 10,000 square feet facility will help the company scale up its R&D operations, meet the growing demand for its clinical services, and expand to new markets.

Today also marks the launch of Lucence’s latest flagship blood test LiquidHALLMARK®. This new test is able to detect 14 types of cancers, 50 genetic mutations and 2 viruses. It is the world’s first blood test that simultaneously detects both cancer-causing genetic mutations and viruses with 99.9% accuracy. This test delivers comprehensive molecular profiling of tumor with one draw of blood using Lucence’s proprietary amplicon-based sequencing technology AmpliMARK™. It detects DNA fragments from cancerous tumors that circulate in the blood to identify tumor-specific genetic mutations, as well as viruses like Hepatitis B, which is associated with liver cancer, and Epstein-Barr, which is associated with nose cancer.

LiquidHALLMARK® will help physicians select the right targeted therapies and immunotherapies for their patients. It will also match patients to clinical trials of new treatments that may help them. This treatment recommendation system is supported by Lucence’s artificial intelligence platform SunTzu.AI™, which integrates clinical data from diverse sources, to develop a personalized treatment strategy for each patient.

Lucence is now also developing a blood test for the early detection of multiple cancers to save lives. The company will launch a clinical study with 100,000 participants across Asia to validate its early cancer detection test this year.

“Lucence’s vision is to achieve zero avoidable cancer deaths through early detection and better treatment selection. Our expanded molecular diagnostics laboratory will be the foundation of that vision. We are glad to have improved the lives of thousands of patients in Asia with our range of blood tests for cancer screening and treatment selection. We will continue to innovate because we want to achieve early detection for all types of cancers to truly save lives,” said Dr. Tan Min-Han.

Speech by Dr. Koh Poh Koon, Senior Minister of State, Ministry of Trade and Industry.

 

About Lucence Diagnostics

Lucence Diagnostics is a genomic medicine company founded to fulfil its vision of a world without avoidable cancer deaths. Lucence invents non-invasive blood tests that improve cancer detection and treatment selection. It targets the most common cancers in Asia using its proprietary technology and AI platform. Lucence is headquartered in Singapore with offices in San Francisco and Hong Kong. Its services are delivered worldwide through an accredited central laboratory. For more information, please visit www.lucencedx.com.

Media Contact

Elena Tan
DID: +65 6906 8567
Email: [email protected]

 

The 5th national Genomics Tumor Board (GTB) meeting in November 2018 was attended by physicians from public and private hospitals in Singapore and Malaysia. Dr David Tan, Consultant Medical Oncologist and Clinician Scientist at the National University Hospital and the founding president of the recently inaugurated Gynaecologic Cancer Group Singapore, shared about the best ways to select precision treatments such as immunotherapy and PARP inhibitors for gynecologic cancer patients.

Dr Tan’s talk was followed by an engaging discussion with the participants on the impact of different genetic mutations on treatment response. In particular, there was strong interest in combinations of PARP inhibitors with other agents for better management of this multi-faceted disease, as well as with immunotherapy sequencing.

The GTB is a national meeting series organised by Lucence Diagnostics for healthcare professionals to discuss and share insights on genomic-based treatment of cancer. This November meeting was supported by the Singapore Society of Oncology and Pfizer. For information on the upcoming meetings in 2019, kindly send us your details through this contact form.

Lucence Diagnostics was delighted to participate in the ESMO Asia 2018 Congress organized by the European Society for Medical Oncology in Singapore from November 23-25, 2018.

At ESMO Asia, we presented our flagship liquid biopsy test, LiquidHALLMARK® – the world’s first blood test to span multiple cancer-causing mutations and viruses – to the oncologists in attendance. LiquidHALLMARK® helps to improve diagnosis and determine the most appropriate treatment for cancer patients. It can also help to monitor treatment response and risk of cancer recurrence.

We were glad to share with Dr Lam Pin Min, Senior Minister of State for Health and Transport for Singapore and Guest-of-Honor of ESMO Asia, about Lucence’s efforts to reducing avoidable cancer deaths through our proprietary liquid biopsy technology.

ESMO Asia is the largest medical conference connecting European and Asian oncologists to the latest advances in cancer care. Lucence is proud to be a part of this year’s event and look forward to future knowledge sharing opportunities with oncology professionals in Europe and the region.

 

Photos

Dr Lam Pin Min, Senior Minister of State for Health and Transport with Dr Min-Han Tan, CEO and Medical Director of Lucence Diagnostics at ESMO Asia 2018.

 

Team Lucence at ESMO Asia 2018.

 

Our account manager John Yi chatting with oncologists at ESMO Asia 2018.

 

Read full article here.

Read full article here.

Read full article here.


Singapore, 23 November 2018 – Lucence Diagnostics, a genomic medicine company focused on personalizing cancer care, and iGenetic Diagnostics, a leading pathology company with operations across India, today announced a partnership to distribute Lucence’s liquid biopsy tests for early cancer detection and treatment in India.

iGenetic will be distributing Lucence’s flagship liquid biopsy test – LiquidHALLMARK®, the world’s first blood test to span multiple cancer-causing mutations and viruses. This test improves cancer diagnosis and treatment selection for patients with advanced cancer. The blood test analyzes the cancer-driving mutations from the DNA shed by the tumor into the bloodstream to determine the best available treatment, which include targeted therapy and immunotherapy.

LiquidHALLMARK® targets a wide range of cancers, especially the cancer types that are most prevalent in Asia, like lung, colon and breast cancers. The turnaround time for this test is also shorter with results coming back in days instead of over a week for current approaches. The test is based on Lucence’s proprietary molecular watermarking technology AmpliMARK™ with sensitivity and specificity of up to 99.9%, which is supported by its AI-powered clinical analytics engine SunTzu.AI™.

iGenetic specialises in providing the full spectrum of pathology solutions including molecular diagnostic services that deliver quicker and accurate results for its customers. The company is headquartered in Mumbai with seven processing labs and over 20 collection centres across India.

“Delivering advanced molecular diagnostics that can enable a quick and precise diagnosis will help to save lives. We are excited to collaborate with Lucence to deliver their proprietary liquid biopsy tests for early cancer detection and better treatment selection to patients in India. Lucence’s technology will help doctors personalize treatment for their patients and improve patient outcomes,’’ said Arunima Patel, CEO, iGenetic Diagnostics.

“Lucence is delighted to collaborate with iGenetic to launch our liquid biopsy tests in India. We are focused on reducing avoidable cancer deaths, particularly in Asia, where more than 4 million cancer deaths occur annually. With iGenetic’s experience and presence in India, we are confident that this partnership will drive better cancer care in India’’, said Dr. Min-Han Tan, Founder and CEO, Lucence Diagnostics.

Media Contacts

 Lucence Diagnostics
Elena Tan
Tel: +65 6592 5102
Email: [email protected]

iGenetic Diagnostics
Arunima Patel
Tel: +91 98205 09449
Email: [email protected]

About Lucence Diagnostics

 Lucence Diagnostics is a genomic medicine company founded to achieve the vision of a world without avoidable cancer deaths. The company is headquartered in Singapore with offices in Hong Kong and San Francisco. Lucence invents genome-based diagnostic tests that enable innovative early cancer detection and treatment selection. Lucence targets the most common cancers in Asia using its proprietary technology and AI-driven genome intelligence. Its key operations are serviced worldwide through an accredited central laboratory. For more information, please visit www.lucencedx.com.

About iGenetic Diagnostics

iGenetic is a next generation diagnostics company focused on the full range of pathological investigations, including specialized cytogenetic and molecular tests in oncology, critical care, gynaecology and neurology. The company is headquartered in Mumbai and operates an accredited central laboratory and a network of labs and collection centres across India. The company has a test menu of over 1400 investigations and is focused on introducing advanced technologies for the Indian population. For more information, please visit www.igenetic.com.

Need Help?